GnRH Agonist Treatment For Prostrate Cancer Increases Diabetes Risk in Men
Sunday, April 30th, 2006According to Boston-based researchers, Gonadotropin-releasing hormone (GnRH) agonist treatment for prostate cancer might increase the chances of diabetes development in nondiabetic men. This observation suggests that hormone therapy increases risk for (type 2) diabetes, a condition defined by insulin resistance.
































